A phase one trial found that Tebentafusp and durvalumab, an anti-PDL1 treatment, was found to be safe and show efficacy, signaling promise for a combination treatment for patients with uveal melanoma (NCT02535078) [66]. The gene discussed is CD274; the disease is uveal melanoma.